Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia

INTRODUCTION: Daratumumab is a human IgGκ monoclonal antibody targeting CD38. Despite the demonstrated benefit of daratumumab in multiple myeloma, not all patients have access to commercially available daratumumab. Here we report a pooled analysis of patients from the UK, Spain, Italy, and Russia en...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, Gordon, Corso, Alessandro, Streetly, Matthew, Mendeleeva, Larisa P., Ptushkin, Vadim V., Chan, Edmond, Ukropec, Jon, Iraqi, Wafae, Al-Akabawi, Assem, Pei, Huiling, Gaudig, Maren, Petrucci, Maria Teresa, Alegre, Adrian, Mateos, Maria-Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139992/
https://www.ncbi.nlm.nih.gov/pubmed/33630275
http://dx.doi.org/10.1007/s40487-020-00137-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139992/
https://www.ncbi.nlm.nih.gov/pubmed/33630275
http://dx.doi.org/10.1007/s40487-020-00137-x

Ejemplares similares